As a result of these processes, the factor weightings were adjusted and the above steps repeated. the final (seventh) version of the scale was then validated using the above steps, and tested in 37 patients (clinic attenders and inpatients in assessment unit) who each had more than one seizure type, including patients with simple partial, complex partial, generalised tonic-clonic, tonic, atonic, absence and myoclonic seizures. It was useful to allow fractionation of scores for factors such as dropping of a held object, falling to the ground, injury and incontinence, according to how commonly these features occurred in seizures.
The evaluation of medical and surgical treat to the 37 patients with two types of seizure, the mean relative severity score of each patient's seizures, obtained by the scale was 8-9, compared with the mean patients' perceived relative severity of 8 5. The mean (SD) difference between the ratios was 0 6 (14-4). The scale, notes on its completion, and the scores obtained by the eight examples of typical seizures that were used in its development, are summarised in the Appendix (see page 876).
Inter-rater reliability data were available for 93 different seizure types, in 57 patients (table) . There was no relationship between the mean of the two observers' scores and the difference between the scores. The mean (SD) difference between the two observers was 1-1 (6 7), the difference between the scores was normally distributed. The limits of agreement were -12-3 and + 14 5, and the coefficient of reliability7 was 13 4. The 95% confidence limits for the mean difference was -0.3 to +2-5, for the lower limit of agreement -14-7 to -9 9, and for the upper limit of agreement + 12 1 to +16-9.
Test-retest reliability data were available for 101 different seizure types, 51 by observer one and 50 by observer two, in a total of 34 patients (table). There was no relationship between the mean of the two scores and the difference between them. The mean (SD) difference between the two sessions was -0-05 (7 9) , the difference scores were normally distributed. 
A scale such as this has to compromise between the conflicting aims of being comprehensive and being workable in clinical practice. The Chalfont Seizure Severity Scale is more appropriate than assigning arbitrary severity scores for different types of seizures, for, example, two for a generalised convulsion and one for a partial seizure,24 for example, a prolonged complex partial seizure may be more disruptive than a brief generalised seizure. The Chalfont Seizure Severity Scale was deliberately not bound by the current classification of seizure types,'0 but was designed to measure, and to be responsive to, the components of seizures that concern patients and their carers.
The assessment of the validity of the scale had to be subjective, but we believe that it was the best achievable. It is open to the criticism that the factor weightings were unduly influenced by professional opinion, but the factors to be included in the scale were generated by open interview of a cohort of patients and their relatives and carers, and particular notice was taken of the views of patients who had two or more types of seizures, as to their relative severity. The resultant factor weightings represented a consensus view; there were occasional idiosyncratic opinions. For example, a patient with simple partial seizures comprising aphasia for 30 seconds (Scale score 1) felt that this was 25% as troublesome as a secondarily generalised convulsion in which he would fall to the ground, and take two hours to return to normal (Scale score 86), his rationale being that he was aware of the episode of aphasia, but unaware of the convulsion.
The inter-rater and test-retest reliability of the scale was reasonable for a profile ofthis type. There was no significant difference between the mean scores on either assessment. The coefficient of reliability was slightly higher in the test-retest situation than for the inter-rater reliability. This would be expected as seizures may have altered in the interval between the two assessments, even though we excluded those patients who had had an obvious change in seizure severity between the two assessments. In the absence of a gold standard it is difficult to judge the clinical importance of a coefficient of reliability of 13 points, we would judge that a change of 10 The scale scores were heavily influenced by the time to return to normal. This factor was, almost invariably, regarded as the most important by patients. We attempted fractionating this factor into 30 minute epochs, but found this to decrease the reliability of the data. The fractionation of scores for the factors: dropping of a held object, falling to the ground, injury, incontinence and automatisms, according to the frequency of their occurrence in a patient's seizures, was found to be a useful sophistication. Otherwise, patients would end up with an unworkable multitude of different seizure types.
We emphasise that the Chalfont Seizure Severity Scale is of seizure severity and is not a measure of the overall impact of epilepsy on a patient's life. The latter is a separate, difficult issue and needs to encompass the unpredictability of seizure occurrence and the fact that an identical seizure may have a greatly different impact on two different patients; for example, a complex partial seizure lasting five minutes with speech automatisms would be likely to be more disruptive to the life of a lawyer than to a gardener.
The Chalfont Seizure Severity Scale has features of both a patient-based and an observer-based scale. The factors to be included were obtained by open interview of patients and carers and factor weightings were affected by the views of patients, carers and professionals. The scale is completed by an observer, but responses are patientdetermined. The scale was developed at a specialised epilepsy clinic and inpatient assessment unit, but will be readily employed in nonspecialised outpatient clinics, and may be completed in a few minutes by a doctor or nurse practitioner.
We believe that the Chalfont Seizure Severity Scale will be particularly useful in longitudinal studies, in which each patient acts as their own control, of the efficacy of medical and surgical treatments; and will also find a role in an epilepsy quality of life schedule, and in correlations with measures of psychiatric, psychological and social morbidity. In common with other data, however, the scale is less likely to be useful for cross-sectional studies. The next stage in the evaluation of the scale, that is in progress, is its inclusion in a prospective, double-blind, placebo-controlled, parallel group AED study, and determination of its reliability when used by non-specialised personnel. A possible further development, that would require careful assessment, may be an evaluation of the combination of the numbers and severity of seizures of different types in a patient, in a unit time, to yield an overall "Epilepsy Activity Index".
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